Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer - sprookjes - yvandenbroek - TriplyDB

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

http://www.wikidata.org/entity/Q28240089

about

KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer Personalized medicine: hope or hype?Markers of resistance to anti-EGFR therapy in colorectal cancer Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options Evolution of management in peritoneal surface malignancies Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes Recent developments in receptor tyrosine kinases targeted anticancer therapy Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Evidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Tumour Cell Heterogeneity Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases Tissue Specific Promoters in Colorectal Cancer Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging Molecular profiling in the treatment of colorectal cancer: focus on regorafenib Treatment of colorectal cancer in the elderly A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Molecular phenotypes of colorectal cancer and potential clinical applications Precision medicine in colorectal cancer: the molecular profile alters treatment strategies Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Inflammation-based factors and prognosis in patients with colorectal cancer Challenges in Antibody Development against Tn and Sialyl-Tn Antigens

P2860

Q21128654-E1A56780-57E8-49A6-AFE2-9ADDF766A7C4 Q21131216-9B4AEE26-DA18-490E-8D62-7A0C3EB990C0 Q21142734-BE62CA83-AED4-4885-B91A-57F23A0B2E29 Q24289193-804DFE24-AB77-47E7-9617-DB94002DF665 Q24598640-A33A7E99-B5C5-4068-92F2-A6B549FE47DB Q24600031-32C13588-394E-4C69-A81A-3C3062CF349D Q24604601-A79C6BF8-0CCC-47D6-B957-A71A45D8ACD9 Q24605057-B8846027-B974-4810-85C4-035539C11E36 Q26738655-16C040C8-7831-4EAA-AE9F-4D6256102065 Q26741293-EB5F63F6-862C-4E57-A4DE-D22190DC2919 Q26747335-47FE71F1-0084-4B76-8F17-5E839464F345 Q26748924-B1E3EB8F-F1C8-45AA-95AF-C6A9862EE785 Q26750691-5D708033-7C9D-4C16-8553-0DB9B63BB5E3 Q26751331-77036C0C-231B-4CAA-A596-D34EFBDBCCAE Q26751344-FE0D825C-1DBF-49E7-A74D-A08C9C5690BF Q26752747-F657EBEF-6052-4633-94CE-2440E563890F Q26765895-51C43FB5-440B-4CB1-AAF5-797E65DDF121 Q26766535-44615E09-2FD6-4AAF-AC81-CC567382DAFD Q26769884-92806F57-254A-4046-B9AD-97D8723C0D67 Q26769958-952ADEDE-D538-4F28-995A-5091F4C23377 Q26772274-4CDFBCD6-0691-46C1-A5F8-9C786E479AD9 Q26773374-119B9D23-E2A6-4895-ACE9-C75FFD55E289 Q26774704-C9FF37EC-0EFF-404E-A803-16C730EDD195 Q26774713-5E015FA6-B2E4-49D5-87AD-07C0E201479F Q26775522-142EFEC0-7AA7-4147-B5E4-3EBC53D5E5FB Q26775949-8A62DCA8-569D-4318-820C-EC281696DD01 Q26777704-5E7B38F6-67C4-4FCA-8747-B82C0748BBC1 Q26778004-C6977FD1-B69A-4B98-815D-0A9EAE58B178 Q26778234-F1576FAF-4E61-46EC-95B8-F3747E337EA9 Q26778296-6392F078-408F-434E-B25E-78730F9F4B89 Q26781457-2F5C3C1F-E182-494E-BE22-ECD6732ED348 Q26782245-F4E3ECA6-E5A9-4EDE-BA91-3B18B71B98E3 Q26783895-1B98474D-07F5-44D0-81E0-63F9594CC2CD Q26784218-F01207A3-429D-4983-8CA3-1940A2E34EF1 Q26785725-21F90C5A-4C9D-49CF-8B8D-C94AAEBC0793 Q26795558-25402651-69D8-4A80-B1D1-F1A2325C16B3 Q26795609-8B839159-5192-4322-97D4-2BB98CFFE685 Q26796348-CB028EDD-E699-4535-BE5D-7351E1329FF1 Q26797425-381972E1-E6CF-4CB6-8435-C31711FBFF3C Q26798183-5A6F756F-2043-4E1F-AC0D-10A5B64D3A73

P2860

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

http://www.wikidata.org/entity/Q28240089

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@ast

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@en

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@nl

type

label

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@ast

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@en

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@nl

prefLabel

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@ast

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@en

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@nl

P1433

Q28240089-3108759F-0022-42F4-B141-1A20CE443708

P1476

Q28240089-23E4D07E-7B2D-4062-9ACD-B161B0CEB754

P2093

Q28240089-1C34B474-43F9-4C84-9D0B-2C613003741A

Q28240089-24AD4B9E-B4B9-45E4-8663-86CA3003B1CD

Q28240089-596F0423-1580-4D5C-AAA2-2E9957181883

Q28240089-78FF8C2A-F54E-447A-B434-38F283A50D35

Q28240089-7E779837-51BB-4CC3-B821-76DEC39F06BF

Q28240089-81EF77E7-E62A-4854-B70A-8B08EE26F2D1

Q28240089-83F8BC95-6D18-4040-80EB-248648F70643

Q28240089-852B4B41-7B0A-491E-BC44-CB3D3E0D6AFC

Q28240089-8D852A2E-CC36-4E16-8E9B-AE26A8A86E20

Q28240089-ADF59113-3C70-4D95-B4D7-523B180FFBE3

P304

Q28240089-523806C2-AE14-4873-9AC2-FD6605CCAC06

P31

Q28240089-A0036C17-B187-499D-A920-7E529AF94718

P3181

Q28240089-F22CB0F3-B075-4264-ADE6-76E03DADCE1D

P356

Q28240089-97341FB1-9B30-4DB4-98D9-EEE8944096D1

P407

Q28240089-EE31A6EB-F8EE-44D5-B21F-41B677E08DAB

P433

Q28240089-ACEDB9B7-90DD-43B2-AB94-95905E6A0A6E

P478

Q28240089-CD85FDFE-6F7F-400F-9756-470B3F029A14

P50

Q28240089-0A2C3619-DDD1-45DF-8191-B317EF770FC2

Q28240089-0A6EC0EA-22AF-403B-BB49-4581B5A03978

Q28240089-18A9A48A-F02D-4E41-840B-0763E386A9FC

Q28240089-31D0B481-69BF-4D52-A834-538E27DD46B7

Q28240089-6E957111-B2EB-4E0A-AF7E-FEAB09A55345

Q28240089-985C6D8C-F91F-4389-9E97-29E5581B9BAF

P577

Q28240089-9C255CCC-2FC0-47B1-860B-684EBC8DEE84

P698

Q28240089-EF14B5F0-DFF1-4CEC-9E73-83E2D613155F

P921

Q28240089-0436D565-B513-4D40-923A-31B05D272874

Q28240089-1B99C6FD-2B67-45A6-8ABD-517DD8364C2A

Q28240089-CAE4623F-1713-45E7-BCFA-A7DD5CBDF6CC

P3181

P356

P1433

The New England Journal of Medicine

P1476

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

@en

P2093

Anatoly Makhson

http://www.w3.org/2001/XMLSchema#string

Christopher Stroh

http://www.w3.org/2001/XMLSchema#string

Chung-Rong Chang Chien

http://www.w3.org/2001/XMLSchema#string

Erika Hitre

http://www.w3.org/2001/XMLSchema#string

Jae Kyung Roh

http://www.w3.org/2001/XMLSchema#string

Jerzy Zaluski

http://www.w3.org/2001/XMLSchema#string

Johannes Nippgen

http://www.w3.org/2001/XMLSchema#string

Michael Schlichting

http://www.w3.org/2001/XMLSchema#string

Paul Ruff

http://www.w3.org/2001/XMLSchema#string

Philippe Rougier

http://www.w3.org/2001/XMLSchema#string

P304

1408-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

562323

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0805019

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

360

http://www.w3.org/2001/XMLSchema#string

P50

Eric Van Cutsem

Claus-Henning Köhne

Gunnar Folprecht

P577

2009-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19339720

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer